Australian TGA Expressed Concern over Shortage of European NBs

| By | EU, Medical Devices, TGA

The TGA (Australian Therapeutic Goods Administration) has expressed concern about a looming shortage of Notified Bodies under the new Medical Device and In Vitro Diagnostics Regulations (MDR/IVDR) in Europe. Not without reason, though.

On July 26, 2019, the TGA has released a Version V1.3 of its guidance “Use of market authorization evidence from comparable overseas regulators/assessment bodies for medical devices (including IVDs)”. Overseas evidence that can be considered now list EU ISO 13485:2016 certificates and gives further clarification on their acceptability:

  • Certificates issued by Notified Bodies designated by the medical device regulators of European member states, under the medical device regulatory frameworks of the European Union
  • ISO 13485:2016 certificates issued by a certification body that is also a Notified Body designated under the IVDD 98/79/EC (for IVD inclusion applications only until 26 May 2022)
  • ISO 13485:2016 certificates issued by a body that is an accredited body that is a signatory to the Multilateral Recognition Arrangement of the International Accreditation Forum (IAF MLA) (for IVD inclusion applications only until 26 May 2022).

According to TGA, the agency will keep a close eye on the readiness and availability of Notified Bodies in Europe and will consider further amendments in Australia, if necessary.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.